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Abstract
Over the years, the knowledge regarding the relevance of the cannabinoid system to the regulation of metabolism has
grown steadily. A central interaction between the cannabinoid system and ghrelin has been suggested to regulate food
intake. Although the stomach is the main source of ghrelin and CB1 receptor expression in the stomach has been described,
little information is available regarding the possible interaction between the gastric cannabinoid and ghrelin systems in the
integrated control of energy homeostasis. The main objective of the present work was to assess the functional interaction
between these two systems in terms of food intake using a combination of in vivo and in vitro approaches. The present
work demonstrates that the peripheral blockade of the CB1 receptor by rimonabant treatment decreased food intake but
only in food-deprived animals. This anorexigenic effect is likely a consequence of decreases in gastric ghrelin secretion
induced by the activation of the mTOR/S6K1 intracellular pathway in the stomach following treatment with rimonabant. In
support of this supposition, animals in which the mTOR/S6K1 intracellular pathway was blocked by chronic rapamycin
treatment, rimonabant had no effect on ghrelin secretion. Vagal communication may also be involved because rimonabant
treatment was no longer effective when administered to animals that had undergone surgical vagotomy. In conclusion, to
the best of our knowledge, the present work is the first to describe a CB1 receptor-mediated mechanism that influences
gastric ghrelin secretion and food intake through the mTOR pathway.
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Introduction
The stimulatory effect of Cannabis sativa on appetite has been
well known for centuries [1]. In recent years, the characterization
of the specific cannabinoid CB1 and CB2 receptors and the
isolation of endogenous cannabinoids have revealed the existence
of an endocannabinoid system. The scientific community has
become increasingly interested in the implications of this system
for body weight regulation; nevertheless, the mechanisms behind
the relationship between this system and body weight regulation
are still not well characterized [2].
Knowledge about energy homeostasis regulation was boosted
with the isolation of ghrelin from the stomach in 1999 [3]; and this
gastric-derived peptide has been proposed to be a link between the
stomach and the central nervous system. The interaction between
ghrelin and the cannabinoid system has previously been proven
via the demonstration of the inhibitory effect of centrally and
peripheral administered rimonabant (an antagonist of the CB1
receptor) on the orexigenic and GH releasing effect of ghrelin [4–
6]. Additionally, it has been reported that both systems depend on
interactions with the AMPK pathway in the hypothalamus and
peripheral tissues [7,8]. Finally, the counteraction of peripheral
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CB1 receptor antagonism on ghrelin orexigenic action has been
described [9]; however, the mechanism behind that interaction has
not been elucidated. Traditionally, the regulation of appetite has
been attributed to the CB1 cannabinoid receptors located in the
brain [10]. However, a functional interaction between endocan-
nabinoid and ghrelinergic systems might be hypothesized to occur
in the gastrointestinal tract [11]. This hypothesis is based on the
expression of CB1 receptors in the epithelium of gastric mucosa,
primarily in the fundus of the stomach where ghrelin is synthesized
and secreted [12]. In support of this, it was observed that CB1
cannabinoid antagonists such as rimonabant have no effect when
directly injected into the brains of food-deprived animals, whereas
systemically administered cannabinoid agents affect food intake
[13,14].
In this context, the hypothesis of the present work is that a
gastric mechanism regulating food intake that depends on the
nutritional status of the animal and is dependent on an interaction
between the cannabinoid system and ghrelin exists. Furthermore,
we postulated that this interaction may be mediated by mTOR
(mammalian target of rapamycin); mTOR is an energy sensor that
is a component of at least two multi-protein complexes: mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
mTORC1 phosphorylates and modulates the activity of the
serine/threonine ribosomal protein S6 kinase 1 (S6K1), which, in
turn, phosphorilates and activate S6, a ribosomal protein involved
in translation [15–17].
Materials and Methods
Ethics Statement
The authors of this manuscript declare that the animal work in
this study was approved by the Animal Care Committee of
Santiago de Compostela University (Santiago de Compostela,
Spain) in accordance with our institutional guidelines and the
European Union standards for the care and use of experimental
animals.
Animal and experimental designs
Sprague-Dawley rats were used. Rats were housed for all
experiments, rats were housed in air-conditioned rooms (22–24uC)
under a controlled light/dark cycle (12 hours light, 12 hours
darkness) with free access to food and water (n = 8–10). The
surgical procedures were performed under anesthesia induced by
intraperitoneal (ip) injection of a mixture of ketamine and xylazine
(ketamine 100 mg/Kg body weight + xylazine 15 mg/kg body
weight). The animals were euthanatized by decapitation. Trunk
blood was collected and immediately centrifuged, and plasma was
stored at –80uC for the biochemical measurements.
Experiment 1: Food intake studies
Adult male rats weighing 250–300 g were implanted with a
chronic intracerebroventricular (icv) cannula as described below
[18]. The amount of food ingested daily by each rat was measured
on days prior to the experiment.
One group of rats had food available ad libitum (fed rats). The
second group was food-deprived for 12 hours before the exper-
iment (nocturnally fasted rats), and the third group was subjected
to surgical vagotomy one week before the experiment and food-
deprived for 12 hours before the experiment (nocturnally fasted
vagotomy rats). Each of the 3 groups was further divided into the
following 4 treatments (n = 8–10): vehicle ip (a solution of saline-
DMSO 70%) plus vehicle icv (saline), vehicle ip (a solution of
saline-DMSO 70%) plus human ghrelin (Global Peptides, Fort
Collins, Colorado, USA) (6 mg/rat icv), rimonabant (3 mg/kg ip)
plus vehicle icv (saline), and rimonabant (3 mg/kg ip) plus human
ghrelin (6 mg/rat icv). Total food intake was assessed at 1, 2, 4 and
6 hours post-injection.
Statistical analyses were performed, and comparisons between
groups were conducted using the Mann-Whitney non-parametric
test.
Experiment 2: Immunohistochemical studies of the
location of ghrelin and CB1 in gastric tissue from ad
libitum fed rats
Immunohistochemistry was performed on sections obtained
from the stomach of the ad libitum fed animals. Immunopositivies
for the CB1 receptor and ghrelin in gastric tissue were examined.
Immunoreactivity for synaptophysin (a marker of neuroendocrine
cells) was also examined. Additionally, the corresponding negative
controls without primary antibodies were performed.
Experiment 3: Variations in plasma ghrelin and gastric
ghrelin secretion in animals with CB1 pharmacological
blockade
3.a. In vivo experiments. To study whether peripheral
block of the endogenous cannabinoid system directly affected
ghrelin secretion by the stomach and plasma ghrelin levels, adult
male rats were assigned to one of eight experimental groups. The
ad libitum fed group received intraperitoneal (ip) injection of
rimonabant (3 mg/kg) (rimonabant) or vehicle (a solution of
saline-DMSO 70%) (Control) 1 hour before the euthanasia, and
the ad libitum animals subjected to surgical vagotomy 1 week before
the experiment were treated with rimonabant ip (3 mg/kg)
(Vagotomy rimonabant) or vehicle (a solution of saline-DMSO
70%, i.e., the Vagotomy group) and euthanatized 1 hour later.
The other four groups received the treatments described above
and were fasted for 36 hours.
Upon decapitation, gastric tissue explants obtained from the
experimental models were incubated as described below [19], and
gastric ghrelin secretion was measured by radioimmunoassay
(RIA) in the culture medium. Additionally, trunk blood was
collected, and ghrelin levels were measured in the plasma with a
commercial kit for radioimmunoassay.
3.b. In vitro experiments. Explants of gastric tissue
obtained from the ad libitum/fasted adult male rats receiving sham
operations or vagotomies (the method described below), were
incubated for 3 h with rimonabant (1 mM) or vehicle. The medium
was collected and ghrelin levels in the culture medium were
measured by RIA.
Two groups of gastric explants from fasting animals were
incubated for 3 h with 2.5 and 5 mM doses of rimonabant.
Experiment 4: Variations in the levels of expression of
ghrelin and CB1 in gastric mucosae
The variations in ghrelin and CB1 mRNA levels in the gastric
mucosae obtained from previously described experimental groups
were examined with real-time PCR. Additionally, ghrelin peptide
contents in the gastric mucosae obtained from the animal groups
listed in Experiment 2a were assayed by Western blotting.
Experiment 5: The effects of pharmacological blockade of
CB1 on the regulation of gastric mTOR signaling
The modulation of gastric mTOR signaling by the peripheral
blockade of the endogenous cannabinoid system was studied.
Adult male rats were assigned to one of the following experimental
groups: 36-hour fasted animals that received vehicle (a solution of
saline-DMSO 70% ip for 6 days) (control), 36-hour fasted animals
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that received vehicle (a solution of saline-DMSO 70% ip for 6
days) and were treated ip with rimonabant (3 mg/kg) 1 hour
before euthanasia (rimonabant), 36-hour fasted animals treated
with rapamycin (1 mg/Kg ip for 6 days) (rapamycin) and 36-hour
fasted animals that were treated with rapamycin (1 mg/Kg ip for 6
days) and ip rimonabant (3 mg/kg) 1 hour before the euthanasia
(rapamycin-rimonabant). Rapamycin was purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
The pmTOR and pS6K1 protein contents of the gastric
mucosae of the animals of these experimental groups were assayed
by Western blot and standardized against the measures of mTOR
and S6K1, respectively.
Experiment 6: Effects of pharmacological blockade of
CB1 on plasma ghrelin, gastric ghrelin secretion and
ghrelin mRNA levels in animals with rapamycin
treatment-induced inhibition of gastric mTOR signaling
The involvement of gastric mTOR signaling in the effect of
the peripheral blockade of the endogenous cannabinoid system
on gastric and plasma ghrelin regulation was studied. Adult
male rats were assigned to one of the following experimental
groups: 36-hour fasted animals (Control), 36-hour fasted
animals treated with rimonabant (3 mg/kg) 1 hour before
euthanasia (Rimonabant), 36-hour fasted animals treated with
rapamycin (1 mg/Kg ip for 6 days) (Rapamycin) and, 36-hour
fasted animals treated with rapamycin (1 mg/Kg ip for 6 days)
and ip rimonabant (3 mg/kg) 1 hour before euthanasia
(Rapamycin-Rimonabant).
Gastric ghrelin secretion from gastric explants and plasma
ghrelin levels were measured by RIA in each of the experimental
groups. Ghrelin mRNA levels in the gastric mucosae were
analyzed with real-time PCR.
Experiment 7: The effects of pharmacological blockade of
CB1 with AM281 on plasma ghrelin, and gastric ghrelin
secretion
To confirm the results obtained with rimonabant, a group of
fasted animals was treated with AM-281 (Tocris Cookson Inc.,
Ellisville, MO), which is a CB1 antagonist that is different from
rimonabant. Adult male rats were assigned to one of 2
experimental groups: the first group of rats were fasted for
36 hours and received an intraperitoneal (ip) injection of AM281
(3 mg/kg) 1 hour before the euthanasia (AM281), the second
group was fasted for 36 hours and received an injection of vehicle
(DMSO), 1 hour before euthanasia (Control). Upon decapitation,
gastric tissue explants obtained from the experimental animals
were incubated as described below [19], and gastric ghrelin
secretion was measured by radioimmunoassay (RIA) with a
commercial kit (Phoenix Pharmaceuticals Inc, USA) in the culture
medium. Additionally, trunk blood was collected, and plasma
ghrelin levels were measured with the commercial radioimmuno-
assay kit.
Experiment 8: Pharmacological blockade of CB1 with
AM281 in the regulation of gastric mTOR signaling
pmTOR and pS6K1 protein contents in the gastric mucosae of
the animal groups described in experiment 7 were assayed by
Western blot and standardized to the measures of mTOR and
S6K1, respectively.
Experimental techniques
Tissue explant culture. Tissue explants were obtained from
adult Sprague-Dawley rats. After euthanasia, the stomach was
rapidly excised and transported to the lab in Krebs-Ringer-
HEPES buffer (NaCl, 125 mmol/l; KCl, 5 mmol/l; MgSO4,
1.2 mmol/l; KH2PO4, 1.3 mmol/l; CaCL2, 2 mmol/l; glucose,
6 mmol/l; HEPES 25 mmol/l; pH=7.4). After removing the
blood vessels and connective tissue, the stomach tissue was washed
with sterile Krebs-Ringer-HEPES buffer. The tissue explants were
placed in six-well dishes containing 2.5 ml of Dulbeccos modified
Eagles medium supplemented with L-glutamine (200 mM),
penicillin (1000 U/ml) and streptomycin (100 mg/ml). After a
pre-incubation period of 1 hour at 37uC under a humidified
atmosphere of 95% air–5% CO2, the media were aspirated, and
2.5 ml of fresh medium was dispensed into each well. The culture
medium was then collected after 2 hours. The samples were stored
at –80uC until the ghrelin assay. The ghrelin levels were measured
by RIA using commercial kits (rat ghrelin RIA, Millipore
Darmstadt, Germany) [20].
Western-blot studies
Whole tissue proteins were prepared by homogenization using a
TissueLyser II (Qiagen, Tokyo, Japan) in cold RIPA buffer
[containing 200 mM Tris/HCl (pH 7.4), 130 mM NaCl, 10%(v/
v) glycerol, 0.1%(v/v) SDS, 1%(v/v) Triton X-100, 10 mM
MgCl2] with anti-proteases and anti-phosphatases (Sigma-Al-
drich;St.Louis, MO). The tissue lysates were centrifuged for 10
minutes at 18000 g in a microfuge at 4uC. Next, equal amounts of
protein (10 or 50 mg/well) were run on sodium–dodecyl sulfate-
polyacrylamide gels (SDS–PAGE) and electroblotted onto nitro-
cellulose membranes. The membranes were probed successively
with primary antibodies and peroxide-conjugated secondary
antibodies (Thermo Scientific, Pierce, Rockford, IL, USA).
Specific antigen-antibody bindings were visualized using a
chemiluminescence method according to the manufacturer’s
instructions (Super Signal West Dura Extended Duration
Substrate, Thermo Scientific, Pierce). Primary anti-ghrelin (C-
18) was purchased from Santa Cruz Biotechnology (CA, USA).
Anti-b-actin (A-5316, Sigma Chemical Co., St Louis, MO, USA),
anti-pmTOR (s2448), anti-mTOR, anti-S6k1 and anti-pS6K1
(Thr389) antibodies from Cell Signaling Technology (MA, USA)
were also used.
Western blots were performed using independent samples from
different rats from each group [20]. b-actin detection was
performed for all western blots as a loading control. The Western
blot data are expressed as the means6SEM of the percentages
normalized to b-actin levels (arbitrary units). Data analyses were
conducted using GraphPad Prism 5 software and the Mann-
Whitney U test and significance is indicated as follows: *p,0.05
and **p,0.01.
RNA isolation and real-time quantitative RT-PCR
Total RNA was isolated from the stomach mucosae of animals
using TRIzol (Invitrogen, CA, USA) according to the manufac-
turer’s recommendations. The extracted total RNA was purified
with DNase treatment using a DNA-free kit as a template
(Ambion, USA) to generate first-strand cDNAs using a High-
Capacity cDNA Reverse Transcription kit (Applied Biosystems,
USA). Quantitative real-time PCR was performed using a
StepOne Plus instrument (Applied Biosystems) with specific
Taqman qRT-PCR primers and probes (Table 1). For analyses,
the ghrelin gene expression levels were normalized to the
expression mRNA levels of the housekeeping gene hypoxanthine
phosphoribosyltransferase 1 (HPRT1) (TaqMan: Applied Biosys-
tems) and are expressed relative to the average value of the control
group.
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Immunohistochemical studies
The gastric wall samples were immersion fixed in 10% neutral
buffered formalin for 24 h and embedded in paraffin. Four
millimeter thick sections were mounted on FLEX IHC
microscope slides (Dako, Glostrup, Denmark) and heated in
an oven at 60uC for 1 h. Immunohistochemical analyses was
automatically performed using an AutostainerLink 48 (Dako).
After deparaffinization and epitope retrieval in EnVision FLEX
target retrieval solution (low pH) for 20 min at 97uC, the slides
were allowed to cool in PT Link to 65uC and then in Dako
wash buffer for 5 min at room temperature. The immuno-
staining protocol included the following: (1) incubation in
EnVision FLEX peroxidase-blocking reagent (Dako) for 5 min;
(2) incubation with ghrelin (C-18) goat polyclonal antibody
raised against a peptide mapping to an internal region of
human-origin ghrelin (Santa Cruz Biotechnology, Santa Cruz,
CA) at a dilution of 1/500 or ready to use synaptophysin
mouse monoclonal antibody Clone SY38 (Dako) or CB1 (H-
150) rabbit polyclonal antibody raised against amino acids 1–
50 mapping to the N-terminus of human-origin CB1 (Santa
Cruz Biotechnology), all for 30 min; and (3) goat antibody to
ghrelin, which involved an LSAB+ System-HRP consisting of
incubation with a universal biotinylated link (15 min) and
streptavidin-HRP (15 min), and for the rabbit antibody to CB1
and mouse antibody to synaptophysin an,incubation with the
EnVision FLEX/HRP (dextran polymer conjugated with
horseradish peroxidase and affinity-isolated goat anti-mouse
and anti-rabbit immunoglobulins) were used (20 min). In
addition, there was an incubation in (4) substrate working
solution (mix) (3,3’-diaminobenzidine tetrahydrochloridechro-
mogen solution) (Dako) for 10 min and (5) EnVision FLEX
hematoxylin (Dako) for 9 min.
Biochemical analysis
Total ghrelin levels were determined via double-antibody RIA
using reagents kits and methods provided by Millipore (Darmstadt,
Germany). The samples for measuring the secretion from the
tissue explants were obtained directly by collecting the culture
medium. The samples were analyzed by RIA as previously
described. The assay sensitivity limit was 93 pg/ml. The results
are expressed as pg/ml of total ghrelin per gram of tissue in the
culture media.
The data are expressed as the means6 SEMs and were assessed
with Mann-Whitney U tests. *p,0.05 was considered significant.
Surgical proceedings
Implantation of intracerebroventricular cannula and
ghrelin treatment. Chronic intracerebroventricular (icv) can-
nulas were implanted under ketamine-xylazine anesthesia (50 mg/
kg, i.p.) as described previously, their targeting of the lateral
ventricle was confirmed with methylene blue staining [18]. The
animals were caged individually and used for the experiments one
week after surgery. During this postoperative recovery period, the
rats became accustomed to the handling procedure under non-
stressful conditions.
Vagotomy
The surgical procedure was performed aseptically, and all
surgical instruments were sterilized before use. The animals
were operated under ketamine-xylazine anesthesia. The rats
were placed on their backs and a midline abdominal incision
was made. The liver was carefully moved to the right to
expose the esophagus. The dorsal and ventral branches of the
vagus nerve were exposed and dissected from the esophagus.
Each branch of the nerve was ligated with surgical sutures at
two points, which were as distal as possible to prevent
bleeding, and cauterized between the sutures. The abdominal
muscles and the skin were then sutured with surgical silk.
Sham surgeries were also performed in which each trunk of
the nerve was exposed but not tied or cauterized. One week
after vagotomy, food intake measurements were performed as
described previously. The effectiveness of the vagotomy was
assessed by post-mortem stomach observation. Only the rats
that exhibited increases in stomach size after the vagotomy
were included in the analyses [21].
Results
Experiment 1: Ghrelin and cannabinoids interact to
regulate food intake
Ghrelin injection induced increases in food intake at 1, 2 and
4 hours; these increases were more evident in the ad libitum group
(control: 0.2960.13, 0.4260.15 and 0.6560.30 vs ghrelin:
1.4560.16, 1.6660.22 and 1.7760.24 grams of food intake at
1, 2 and 4 hours, resepectively; Figure 1A) than in the animals that
were fasted overnight (control: 4.6560.67, 5.4660.79 and
7.0260.79 vs ghrelin: 6.7460.55, 7.0560.77 and 8.8860.72
grams of food intake, respectively; Figure 1B).
Peripheral treatment with rimonabant decreased basal food
intake in the overnight fasted animals (Figure 1B; control:
4.6560.67 vs rimonabant: 2.7460.39 grams of food intake at 1
hour; p,0.05). However, this treatment had no effect on the
satiated animals (control: 0.29860.13 vs rimonabant: 0.12860.09
grams of food intake; Figure 1A).
Ghrelins orexigenic action was blocked by peripheral injections
of rimonabant in both overnight fasted animals (ghrelin:
6.7460.55 vs. ghrelin+rimonabant: 3.0860.37 grams of food
intake; p,0.01; Figure 1B) and satiated animals (ghrelin:
1.4560.163 vs. ghrelin+rimonabant: 0.30660.12 grams of food
intake; p,0.01; Figure 1A).
Surgical vagotomy blocked the anorexigenic effects of rimona-
bant on both basal food intake and ghrelin-stimulated food intake
(Figure 1C).
Table 1. Primers for the real time qPCR analyses.
Gene symbol Gene description
TaqMan gene expression
assay number GenBank accession number
HPRT hypoxanthinephosphoribosyltransferase 1 (REFERENCE GENE) Rn01527840_m1 NM_012583.2
GHRL ghrelin/obestatin prepropeptide Rn01425835_m1 NM_021669.2
CNR1/CB1 cannabinoid receptor 1 (brain) Rn00562880_m1 NM_012784.4
doi:10.1371/journal.pone.0080339.t001
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Experiment 2: Immunohistochemical studies of the
locations of ghrelin and CB1 receptors in gastric tissue
from ad libitum fed rats
To investigate whether CB1 receptor were present in the
endocrine cells of the stomach, immunohistochemical analyses
using specific antibodies for CB1 and ghrelin were performed on
gastric fundus sections obtained from ad libitum fed rats.
Immunoreactivities for ghrelin and CB1 were found in small
dispersed cells situated primarily at the bottom of the gastric
glands (Figure 2A and B). The size, morphology and distribution
of these cells let us to identify them as neuroendocrine cells.
Additionally, synaptohysin inmmunoreactivity confirmed the
neuroendorine nature of these cells (Figure 3C). The negative
control without CB1 or ghrelin antibodies is shown in Figure
2D.
Experiment 3: Variations in plasma ghrelin and gastric
ghrelin secretion in animals with CB1 pharmacological
blockade
3.a. In vivo. Rimonabant treatment (ip) of ad libitum fed rats
did not affect gastric ghrelin secretion, in either the sham operated
rats or in vagotomized animals (Figure 3A). Surgical vagotomy
increased gastric ghrelin secretion in the fed animals (fed:
7884.06419 pg/ml/g tissue vs fed vagotomy: 1175861043 pg/
ml/g tissue; p,0.05). As expected, food restriction for 36 hours
increased gastric ghrelin secretion with respect to the ad libitum
animals (fed: 7884.06419 pg/ml/g tissue vs fast:
11060.06559.5 pg/ml/g tissue; p,0.01, Figure 3A and B).
Surprisingly, rimonabant treatment of the fasted animals reversed
the increased levels of gastric ghrelin secretion induced by the food
deprivation (fast: 11060.06559.5 pg/ml/g tissue vs. fast rimona-
bant: 77966430.9 pg/ml/g tissue; p,0.01), and this effect was
not observed in vagotomized animals subjected to food depriva-
tion (fast vagotomy: 87496832 pg/ml/g tissue vs fast vagotomy
rimonabant: 1064961314 pg/ml/g tissue; no significant differ-
ence, Figure 3B). Vagotomized animals in the fasting condition,
exhibited a non-significant decrease in gastric ghrelin secretion
compared to the control group (Figure 3B).
In keeping with the ex vivo data, rimonabant treatment did not
affect circulating ghrelin levels in the ad libitum animals (Figure 3C).
Increased circulating ghrelin levels were observed in the fasted
animals relative to the ad libitum group (fed: 1797673 vs fast:
35596462 pg/ml; p,0.01) but were unaltered in the vagoto-
mized animals (fed vagotomy: 1984687.2 vs fast vagotomy:
20396138 pg/ml) (Figure 3C and D). Similar to gastric ghrelin
secretion, pharmacological cannabinoid receptor blockade pre-
vented the food-deprivation induced increase in circulating ghrelin
levels (fast: 35596462 pg/ml vs. fast rimonabant: 22116141 pg/
ml; p,0.01) (Figure 3D).
3b. Variation in ghrelin secretion from gastric ex-
plants in vitro treated with rimonabant. Vagotomized
Figure 1. Food Intake measures in rats after icv treatment with
ghrelin/vehicle (6 mg/rat) and ip treatment with rimonabant
(3 mg/kg ip)/vehicle under different nutritional statuses: A) Ad
libitum fed, B) nocturnal fasting, c) animals subjected to
overnight fasting and previously subjected to surgical vagot-
omy. *vs control, #vs. rimonabant+ghrelin.
doi:10.1371/journal.pone.0080339.g001
Figure 2. Immunohistochemical studies of the locatizations of
ghrelin (A) and CB1 (B) in gastric tissue from ad libitum fed rats.
Inmunoreactivities for both antibodies were found in isolated
neuroendocrine cells primarily that were primary located at the bottom
of the gastric glands. Labeling of neuroendocrine cells with synapto-
physin is shown in panel (C). The corresponding negative control (D).
Magnification 40x.
doi:10.1371/journal.pone.0080339.g002
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animals exhibited increased gastric ghrelin secretion (fed:
75716538 pg/ml/g tissue vs fed vagotomy: 1221861115 pg/
ml/g tissue; p,0.01; Figure 3E). Gastric explants from the fasted
animals exhibited higher levels of ghrelin secretion than those from
the ad libitum fed animals (fed: 75716538 pg/ml/g tissue vs fast:
113946901 pg/ml/g tissue) (Figure 3E and F). In contrast to the
Figure 3. Gastric ghrelin secretion from tissue explants obtained from ad libitum fed animals (A) or 36-hour fasted animals (B) and
plasma ghrelin levels from ad libitum fed animals (C) or 36-hour fasted animals (D) under different in vivo treatments (control/
rimonabant), and surgical procedures (vagotomy/sham operated). Gastric ghrelin secretion from tissue explants from ad libitum fed animals
(E) or 36-hour fasted animals (F) under different in vitro treatments (control/rimonabant) and surgical procedures (vagotomy/sham operated). *vs
control.
doi:10.1371/journal.pone.0080339.g003
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in vivo data, rimonabant directly added to the stomachs of food-
deprived animals was not able to revert the increased levels of
gastric ghrelin secretion induced by fasting (fast: 113946901 pg/
ml/g tissue vs fast rimonabant: 1273962294 pg/ml/g tissue; no
significant difference) (Figure 3F).
To reconfirm the lack of effect of rimonabant directly added to
stomachs of food-deprived animals, two additional doses of
rimonabant were tested (2.5 and 5 mM). These doses were not
able to revert the increased levels of gastric ghrelin secretion
induced by fasting (fast: 1535161826pg/ml/g tissue vs fast
rimonabant (2.5 mM): 107926560 pg/ml/g tissue, fast rimona-
bant (5 mM): 1346663050 pg/ml/g tissue; no significant differ-
ence) (Figure S1).
Experiment 4: Variations in the expression levels of
ghrelin and the CB1 receptor
A decrease in ghrelin mRNA levels was observed in animals
subjected to surgical vagotomy (fed: 160.15 arbitrary units vs fed
vagotomy: 0.7860.04 arbitrary units; fed rimonabant: 0.960.23
vs fed vagotomy rimonabant 0.5760.08 arbitrary units; p,0.05)
(Figure 4A).
Fasting for 36 hours did not affect the gastric ghrelin mRNA
with respect to the ad libitum animals, although a slight tendency
toward an increase in ghrelin mRNA was observed (fed: 160.15
vs fast: 1.0560.13 arbitrary units; ns). However, rimonabant
treatment (ip) of fasted animals slightly decreased ghrelin
mRNA levels (fast: 1.0560.13 arbitrary units vs. fast rimona-
bant: 0.860.05 arbitrary units), but this difference was not
statistically significant (Figure 4B). Ghrelin mRNA levels were
not changed in the vagotomized fasted animals (fast: 1.0560.13
vs fast vagotomy: 1.160.11). Additionally, rimonabant treat-
ment did not induce any effects in the animals subjected to
surgical vagotomy (Figure 4B).
Rimonabant treatment of fasted animals increased the ghrelin
contents of the stomachs (rimonabant: 120.68% vs control fast;
p,0.01) (Figure 4D). Additionally, as shown in the representative
western blot in Figure 4, the fasted animals exhibited lower
stomach ghrelin contents compared to the fed animals (fast: 62.7%
over control fed; p,0.01) (Figure 4C and D).
Rimonabant treatment (ip) of the ad libitum fed rats did not affect
gastric CB1 mRNA levels in either the sham operated rats or the
vagotomized animals (Figure 4E). However, vagotomy per se
decreased CB1 mRNA expression (fed: 1.0560.11 vs fed
vagotomy: 0.4460.05, p,0.01; fed vagotomy rimonabant:
0.3460.05; p,0.01) (Figure 4E).
In contrast to ghrelin, CB1 mRNA levels decreased (Figure 4F)
significantly after peripheral rimonabant treatment of fasted
animals (fast: 1.0660.13 vs fast rimonabant: 0.3660.03 arbitrary
units; p,0.01).
Experiment 5: The effects of pharmacological blockade of
CB1 on gastric mTOR signaling
Gastric CB1 blockade by rimonabant treatment in the fasting
state induced activation of the mTOR/S6K1 pathway as
demonstrated by the pmTOR and mTOR data, which are
expressed as percentages over control, (fast: 100 vs rimonabant:
224.58642.83 pmTOR/mTOR; p,0.05). Additionally, rimona-
bant treatment was not able to reverse the blockade of the
mTOR/S6K1 pathway that was elicited by rapamycin (rapamy-
cin: 104.5616.92 vs rapamycin+rimonabant: 87.75613.85
pmTOR/mTOR; Figure 5A).
Gastric phospho-S6K1 responded to rimonabant treatment in a
manner similar to that of pmTOR (control: 100 vs. rimonabant:
143.5866.47 pS6K1/S6K1; no significant difference). Addition-
ally, and in accordance with previous studies, the intracellular
pathway was inhibited by rapamycin treatment (control: 100 vs.
rapamycin: 43.8665.20 pS6K1/S6K1), and under this condition,
rimonabant did not affect pS6K1 (rapamycin+rimonabant:
64.41610.13 pS6K1/S6K1) (Figure 5 B). All the values are
represented as percentages over control.
Experiment 6: The effects of pharmacological blockade of
CB1 on plasma ghrelin and gastric ghrelin secretion in
animals with inhibited gastric mTOR signaling
Blockage of the mTOR pathway with chronic rapamycin
treatment blocked the effects of rimonabant on gastric ghrelin
secretion (Figure 6A), ghrelin mRNA expression in gastric
mucosae (Figure 6B) or circulating ghrelin levels (Figure 6C).
However, the groups that received rapamycin treatment exhibited
higher levels of gastric ghrelin secretion (Control: 110606559 vs
rapamycin: 1645265489 pg/ml/g of tissue; rimonabant:
779664741 vs rapamycin+rimonabant: 2333764741 pg/ml/g
of tissue, p,0.01). Similarly, plasma ghrelin levels were increased
in the animals that received rapamycin treatment (control:
35596445 vs rapamycin: 43506375 pg/ml/g of tissue; rimona-
bant: 22116141 vs rapamycin+rimonabant: 31606504 pg/ml/g
of tissue, p,0.01).
Experiment 7: The effects of pharmacological blockade of
CB1 with AM281 on plasma ghrelin and gastric ghrelin
secretion
To confirm the inhibitory effects of the blockade of the
peripheral CB1 receptors on gastric ghrelin secretion from the
stomach and plasma ghrelin levels, several measures were
performed on samples from fasting animals treated with an
alternative CB1 antagonist (AM281).
AM281 treatment (ip) of fasted animals inhibited the elevated
levels of gastric ghrelin secretion induced by food deprivation (fast:
2617062786 pg/ml/g tissue vs fast AM281:
14222.7861329.3 pg/ml/g tissue; p,0.01 (Figure 7A).
Corroborating ex vivo data, pharmacological cannabinoid
receptor blockade with AM281 prevented food-deprivation-induced
increases in circulating ghrelin levels (fast: 1424699.96 pg/ml vs fast
rimonabant: 876667.25 pg/ml; p,0.01) (Figure 7B).
Experiment 8: The effect of pharmacological blockade of
CB1 with AM281 on the regulation of gastric mTOR
signaling
Corroborating the effects of rimonabant, gastric CB1 blockade
wit AM281 treatment in the fasting state induced activation of the
mTOR/S6K1 pathway as demonstrated by the pmTOR and
mTOR data, which are expressed as percentages over control,
(control: 100 vs. AM281: 166.72610.66 pmTOR/mTOR;
p,0.05, Figure 8A).
As rimonabant treatment, gastric phospho-S6K1 responded to
AM281 treatment in a manner similar to that pmTOR, although
the phospho-S6K1 response did not reach statistical significance
(control: 100 vs AM281: 116.7169.04 pS6K1/S6K1; no signif-
icant difference, Figure 8B). All values are represented as the
percentages over control.
Discussion
The main findings of the present work are as follows: 1)
peripheral CB1 receptors modulate food intake through a
mechanism that implies gastric ghrelin regulation that requires
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intact vagal communication; 2) CB1 receptors are localized in the
neuroendocrine cells of the stomach; and 3) Gastric CB1 receptors
modulate gastric ghrelin secretion at the intracellular level through
the mTOR pathway.
Previous studies have suggested that the endocannabinoid
system is involved in appetite and feeding [22], and multiple
experimental protocols have demonstrated the food intake-
reducing effects of rimonabant, which is an antagonist of the
Figure 4. mRNA expression levels measured by real-time PCR for ghrelin in ad libitum fed animals (A) or 36-hour fasted animals (B).
Ghrelin protein levels and representative Western blot from the mucosa from ad libitum fed animals (C) or 36-hours fasted animals (D). Animals that
received different in vivo treatments (control/rimonabant) and surgical procedures (vagotomy/sham-operated). C: control, R: rimonabant, V:
vagotomy; V+R: vagotomy+rimonabant. CB1 receptor mRNA levels in the gastric mucosae of ad libitum fed animals (E) or 36-hour fasted animals (F)
and animals that received different in vivo treatments (control/rimonabant) and surgical procedures (vagotomy/sham operated). *vs control.
doi:10.1371/journal.pone.0080339.g004
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CB1 receptor. Accordingly, in the present work, peripherally
injected rimonabant was found to prevent the increase in food
intake elicited by central ghrelin administration (Figure 1A and B).
Moreover, a more surprising finding was that rimonabant perse was
able to induce a reduction in basal food intake amounts but only in
the animals that were fasted overnight (Figure 1B). However, the
anorexigenic effects of rimonabant disappeared if the animals had
previously been subjected to surgical vagotomy (Figure 1C); this
finding highlight the requeriment of an intact vagus connection for
the effects of the cannabinoid system on appetite. This finding has
previously been suggested by the work of Gomez et al., who
demonstrated that systemic capsaicin treatment, which selectively
destroys unmyelinated visceral afferents, blocks the inhibitory
effect of rimonabant [13]. However, another study from Madsen
Figure 5. Measures of pmTOR/mTOR levels in gastric mucosa
and representative Western blots from animals in the fasting
state treated with ip rimonabant and/or ip rapamycin chron-
ically for 1 week (A). Phospho-S6K1/S6K1 in gastric mucosae from
animals in the fasting state treated with rimonabant ip and/or
rapamycin ip chronically for 1 week (B). The results are expressed as
percentages over control (phospho-S6K1/S6K1). *p,0.05, vs control;
#p,0.05 vs rimonabant. C: control, R: rimonabant, Ra: rapamycin; Ra+R:
rapamycin+rimonabant.
doi:10.1371/journal.pone.0080339.g005
Figure 6. Gastric ghrelin secretion (A). Ghrelin mRNA levels
measured by real-time PCR in the gastric mucosae (B) and plasma
ghrelin levels (C) from animals in fasting states treated with ip
rimonabant and/or ip rapamycin chronically for 1 week.
doi:10.1371/journal.pone.0080339.g006
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et al. demonstrated that intact vagal afferents are not required for
the anorexigenic action of rimonabant [23]. The main difference
between the work of Madsen et al. and the present study was the
administration route. In the previous study, rimonabant was
administered via oral gavage, whereas in our work and the work of
Gomez rimonabant was administered intraperitoneally.
It has been repeatedly shown that animals in fasting states
exhibit increased levels of ghrelin that induce orexigenic effects
mainly via the activation of the vagus nerve [24,25], and the
present study supports the possibility that peripheral rimonabant
acts locally at the gastric level to reduce ghrelin secretion and
consequently, downregulate food intake. The immunohistochem-
ical studies performed in the present work showed that the
neuroendocrine cells producers of ghrelin are distributed near the
CB1-positive cells in the stomach and have patterns of distribution
that are similar to those of the CB1-positive cells (Figure 2). CB1
expression in rats has been described in pre and postganglionic
cholinergic neural elements that innervate the smooth muscle and
mucosal and submucosal blood vessels [26]. However, these
studies did not demonstrate the localization of these receptors to
the neuroendocrine cells of the stomach.
After finding an anorexigenic effect of rimonabant on basal and
ghrelin-stimulated food intake and immunopositivity for CB1 and
ghrelin in the neuroendocrine cells of the stomach, we next
determined whether the interaction between these systems was
mediated locally in the stomach. To do this, we used an organ
culture model of gastric tissue that was previously developed and
validated by our group [19,20,25,27]. With this model, peripher-
ally administered rimonabant was shown to reverse the gastric
increase in ghrelin secretion induced by fasting (Figure 3B).
However, in fed animals, which exhibit basal levels of ghrelin
secretion, the administration of rimonabant failed to produce any
effect (Figure 3A). The present data support the results obtained
Figure 7. Gastric ghrelin secretion from tissue explants (A) and
plasma ghrelin levels (B) obtained from 36-hour fasted animals
that received in vivo treatment with AM281 (3 mg/Kg ip).
**p,0.01.
doi:10.1371/journal.pone.0080339.g007
Figure 8. Measures of pmTOR/mTOR in the gastric mucosae
and representative Western blots from animals in the fasting
state treated with ip AM281 or vehicle (A). Phospho-S6K1/S6K1 in
the gastric mucosae and representative Western blots from animals in
the fasting state treated with ip AM281 or vehicle (control) (B). The
results are expressed as percentage over control (phospho-S6K1/S6K1).
*p,0.05.
doi:10.1371/journal.pone.0080339.g008
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from the food intake studies in which the administration of
rimonabant to fed animals did not produce an anorexigenic effects
(Figure 1A), but did produce strong effects in overnight fasted
animals (Figure 1B). In the light of this finding, we can affirm that
the modulation of gastric ghrelin secretion by CB1 is required for
the anorexigenic effect of antagonists of this receptor. Moreover,
in accordance with the lack of effect of rimonabant on food intake
in vagotomized animals (Figure 1C), the gastric studies of the
present work indicate that the inhibition of ghrelin by rimonabant
was abolished after vagotomy (Figure 3B), which, in turn, indicates
that the vagus connection needs to be intact to ensure efficient
interactions between ghrelin and CB1. Consequently, in the in
vitro experiment in which, gastric tissues received one rimonabant
treatment in isolation from the complete organism (i.e., the vagus
enervation was not fully operational), inhibition of ghrelin by
rimonabant was not observed (Figure 3E and F). To corroborate
these results and to assess whether the secretion of ghrelin by the
stomach is reflected in circulating ghrelin levels, the plasma ghrelin
levels of the experimental groups were measured. As shown in the
Results section (Figure 3D and 7B), the peripheral antagonism of
CB1 was reflected by a decrease in circulating ghrelin levels, which
was a consequence of the reduction of ghrelin secretion from the
stomachs of the fasted animals. These data corroborate the
findings of other authors who have described the regulation of
ghrelin plasma levels by peripheral treatment with different
agonists or antagonist of the CB1 receptor [28,29].
The studies of the secretion, protein contents and mRNA levels
of ghrelin in gastric tissue allowed us to establish a gastric
mechanism for the regulation of ghrelin by cannabinoids. The
above mentioned mechanism was clearly demonstrated by the
decrease in ghrelin secretion from the stomach (Figure 3B) that
was induced by rimonabant ip treatment; this reduction in ghrelin
secretion was accompanied by increased amounts of protein
storage in the ghrelin-positive cells (Figure 4D), as measured by
Western blot, which was accompanied by no effect on ghrelin
mRNA levels (Figure 4B). Moreover, an increase in gastric ghrelin
secretion by the fasted animals compared to the ad libitum fed
group was observed (Figure 3A and B); this finding was reflected
by the reduced ghrelin content inside the cells as shown by
Western blots (Figure 4E and F). Together, the data presented in
the present work reinforce the physiological mechanism of the
regulation of gastric ghrelin secretion that has previously been
reported in other conditions by our group [20].
The CB1 mRNA expression levels in the gastric mucosae were
assayed with real-time PCR in the experimental models, and, to
us, the most interesting findings was the significant decrease in
CB1 mRNA levels in the stomachs of fasted animals after
peripheral rimonabant treatment and the lack of an effect in the
fed animals (Figure 4E and F). These data reinforce the finding
that the effects of rimonabant on ghrelin and the regulation of food
intake are observed only in fasted animals. The rimonabant
induced downregulation of CB1 might be associated with the
decreases in ghrelin secretion by the stomach [11]. In contrast,
surgical vagotomy induced decreases in CB1 receptors in both fed
and fasted animals, which might explain the lack of effect of
rimonabant on food intake in the animals subjected to surgical
vagotomy (Figure 1C).
The second part of this study focused on the search for the
intracellular mechanism responsible for the interaction between
ghrelin and the endocannabinoid system in the stomach. The
possible role of the mTOR pathway in mediating the gastric
interaction between ghrelin and endocannabinoid system was
explored. To the best of our knowledge, our study is the first to
demonstrate that the acute administration of rimonabant or
AM281 to fasted animals activates the mTOR/S6K1 pathway as
demonstrated by the increases in the phosphorylation of mTOR
(Figure 5A and 8A) and the non-significant trend towards
increased phophorylation of S6K1, a downstream effector of
mTOR (Figure 5B and 8B). In accordance with our results, it has
previously been described that mTOR phosphorylation in the
gastric mucosa is downregulated by fasting, and we demonstrated
that this effect was reverted after rimonabant administration
(Figure 5A). It has previously been reported that the inhibition of
gastric mTOR signaling leads to increased expressions of ghrelin
mRNA, GOAT mRNA, tissue preproghrelin content and
circulating ghrelin and that there is an inverse relationship
between gastric mTOR signaling and ghrelin expression and
secretion during changes in energy status [30]. Accordingly, in the
present paper, the decreases in gastric ghrelin secretion (Figure 3B
and 7A) and circulating ghrelin (Figure 3D and 7B) levels that
were observed in the fasted animals treated with rimonabant or
AM281 coincided with increase in mTOR and S6K1 phosphor-
ylation (Figure 5A and B and Figure 8A and B).
Finally, we confirmed our results using an in vivo model in
which the mTOR/S6K1 pathway was blocked with the objective
of proving the key role of this intracellular pathway in this gastric
system. To do this, the effects of the administration of rimonabant
to fasting animals that had received chronic rapamycin treatment
on gastric and plasma ghrelin levels were tested. Rimonabant
treatment did not affect mTOR or S6K1 phosphorylation in
animals that has been treated with rapamycin (Figure 5A and B).
Moreover, the injection of rimonabant into the fasted animals
whose mTOR pathways had been blocked by rapamycin
treatment did not affect gastric ghrelin secretion (Figure 6A),
ghrelin mRNA (Figure 6B) or circulating ghrelin levels (Figure
6C), thus demonstrating that the mTOR pathway is responsible
for the interaction between the endocannabinoid system and
ghrelin at the gastric level. However, the involvement of additional
gastric-level signaling routes in this system should not be excluded
and the futures studies should focused on identifying additional
intracellular pathways involved in this system of gastric regulation.
In summary, to the best of our knowledge, these data
demonstrate for the first time that pharmacological blockade of
the cannabinoid receptor via peripheral rimonabant treatment is
sensed by gastric cells as a satiety signal that is comparable to food
intake, as shown by the activation of the mTOR/S6K1 pathway.
Consequently, the gastric tissue responds by inhibiting the
increased ghrelin secretion that is normally observed in fasting
states, which results in decreased food intake due to decreased
vagally mediated orexigenic signaling to the brain.
In conclusion, the present work demonstrates the existence of a
gastric mechanism for the interaction between the endogenous
cannabinoid system (CB1) and ghrelin that is mediated throught
the intracellular mTOR pathway and, results in a physiological
effect on the regulation of food intake that requires the vagus
nerve. This paper used molecular, physiological and surgical
approaches to highlights the metabolic action of the gastric tissue
that emerges as a result of the complex network of relevant
endocrine systems. Additionally these data provide new clues for
the understanding of the complex mechanisms of the regulation of
food intake.
Supporting Information
Figure S1 Gastric ghrelin secretion from tissue explants from
36-hour fasted animals that received different in vitro treatments:
vehicle (control), rimonabant (2.5 mM) or rimonabant (5 mM).
(TIF)
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